Covetrus Announces New Structure, Focus and Strength within Europe
21.12.2021 16:00:00 EET | Business Wire | Press release
Covetrus® (Nasdaq: CVET), a global leader in animal-health technology and services, today announced a new organizational structure within Northern and Central Europe to execute the company’s three-year strategy, deliver operational efficiencies, and better enable the company’s combined commercial teams to service their customers and provide a reset for the German and U.K. businesses.
Earlier this year, Covetrus announced the hiring of András Bolcskei as Covetrus’ first president of International. Mr. Bolcskei was charged with bringing all commercial teams outside of North America together, and today’s announcement advances that plan. Key changes include the development of a new International leadership team and a concerted focus within the U.K. and German businesses, an anticipated element of the company’s strategic plan, as well as an immediate and strong reaction to recent pressures within those two regions.
Covetrus Germany will move its DACH headquarter from Hamburg to Düsseldorf. Effective April 1, 2022, Covetrus’ Düsseldorf location will create the DACH hub for the company under the leadership of Dr. Andreas Tschuor and will restrengthen its commercial capabilities, service to customers and competitiveness within the German market. In addition, the proximity of Düsseldorf to two other Covetrus regions (Belgium and the Netherlands) will enable and lead to increased efficiencies and operational excellence within those regions’ commercial teams. The company will close its Hamburg office on March 31, 2022. Employment contracts tied to Hamburg will be discontinued, and employees will be offered the choice to continue employment with unchanged conditions in the new Düsseldorf office on April 1, 2022.
Development of a new leadership team to drive the company’s International Business. Effective January 1, 2022, and similar to the structure adopted in the U.S. earlier this year, the U.K. commercial and the Global Technology Solutions (GTS) teams, and the U.K. & Europe sales teams will come under one, unified commercial leadership, led by Loic Jegou, Country Manager and VP, Northern Europe. Mr. Jegou joined Covetrus last month with 18 years of experience in the animal health pharmaceutical business at Pfizer and MSD Animal Health. The U.K. business will increase service to U.K.-based customers through an extended focus of the company’s “One Face to Customer” approach. Additionally, in keeping with a true International approach, Australia and New Zealand are adopting the same go-to-market strategy, and the GTS sales team within the APAC region will report directly to Simon Hellams, VP, APAC. Covetrus is uniquely suited, within the animal health industry, to meet their customers’ overall needs with a single point of contact due to Covetrus’ expansive product and service offering and breadth of capabilities.
“These moves position Covetrus to win for our European customers and win for our global business,” said Ben Wolin, President & CEO. “I have absolute confidence in our ability to drive our strategy, win back our position within the German and U.K. markets, drive greater outcomes for our customers and the animals they care for … and drive success for all our teams and stakeholders.”
About Covetrus
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine with more than 5,500 employees serving over 100,000 customers around the globe. For more information about Covetrus visit https://covetrus.com/.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005247/en/
Contact information
Investor Contact
Nicholas Jansen
nicholas.jansen@covetrus.com
(207) 550-8106
Media Contact
Mona Downey
mona.downey@covetrus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom